Lifetime Medical Spending Attributed to Incident Type 2 Diabetes in Medicare Beneficiaries: A Longitudinal Study Using 1999–2019 National Medicare Claims
Authors' conclusion
The large lifetime incremental medical spending associated with incident T2D underscores the need for preventing T2D among Medicare beneficiaries. Our results could be used to estimate the potential financial benefit of T2D prevention programs both overall and among subgroups of beneficiaries.
Study context
- Population
- Medicare fee-for-service beneficiaries with incident T2D diagnosed 2001–2003, followed until death, disenrollment or end of 2019matched cohort
- Exposure
- Newly diagnosed T2D vs matched nondiabetes cohort
- Outcome
- Lifetime incremental medical spending attributed to incident T2D (2019 U.S. dollars), by age at diagnosis, sex and race/ethnicity
- Follow-up
- From age at T2D diagnosis to death
Methodological detailspropensity-score matched, 100% Medicare fee-for-service claims 1999–2019
- Propensity-score matched
- 100% Medicare fee-for-service claims 1999–2019
Main finding
As reported in the abstract
Lifetime medical spending
Higher lifetime medical spending with newly diagnosed T2D vs comparable group without diabetes, despite shorter life expectancy
36-40%
Lifetime incremental medical spending range, depending on age at diagnosis, sex and race/ethnicity
$16,115 to $122,146
Observational data: associations, not effects.
Original publication
Lifetime Medical Spending Attributed to Incident Type 2 Diabetes in Medicare Beneficiaries: A Longitudinal Study Using 1999–2019 National Medicare Claims. Diabetes Care. Published 24 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →